Novo Nordisk Chief Executive Peter Doustdar indicated that mergers and acquisitions remain a strategic priority to strengthen the company’s pharmaceutical pipeline, even as investor sentiment appears tempered by the breadth of the firm’s long-term outlook. The comments followed a volatile trading session in which Novo Nordisk shares fell nearly 8 percent on Monday, marking its worst single-day performance since February, before settling just below the flatline at a 0.75 percent decline.
“I think yesterday we laid out a more clear strategy of the direction we want to take the company at. We talked about diversification of the company, but yet the reaction tells me that there’s still some work to do in convincing some of the investors,” Doustdar said. The company projected the release of more than five “multi-blockbuster” drugs by 2030, forecasting sales exceeding 150 billion Danish kroner ($23 billion) by 2035. Additionally, Novo Nordisk guided for revenue growth aligned with industry peers, including Eli Lilly, AstraZeneca, Amgen, Biogen, Merck, AbbVie, and Novartis.
Despite the strategic clarity, analysts noted that the plans disappointed some investors who had anticipated a more dramatic acceleration. Because Novo Nordisk’s targeted growth mirrors that of its competitors, it signaled slower progress than many had hoped, according to CNBC reports on Monday. In contrast, Novo’s primary U.S. rival Eli Lilly has secured a dominant share of the weight-loss market with its injectable GLP-1 drugs Mounjaro and Zepbound, despite entering the space years after Novo Nordisk.
Eli Lilly CEO David Ricks told CNBC on Monday that approximately one-third of new GLP-1 patients are now utilizing the company’s oral weight-loss pill, Foundayo. “We’re confident long term,” Ricks stated. The divergence in market performance is evident in stock trajectories: Novo Nordisk shares have declined 34 percent over the past year, whereas Eli Lilly stock has risen just over 54 percent during the same period.
Eli Lilly’s oral pill success is terrifying. Novo needs to accelerate pipeline diversification immediately or they’ll lose their dominant position entirely.
Is the market punishing Novo for playing it safe? Doustdar’s strategy sounds logical, but the stock reaction suggests investors have zero patience.
I’m honestly shocked Novo dropped 8 percent for guidance that mirrors competitors. Investors clearly wanted Eli Lilly-level aggression, not steady growth.